Роль D-маннозы и проантоцианидинов клюквы в профилактике рецидивов инфекции мочевыводящих путей

Роль D-маннозы и проантоцианидинов клюквы в профилактике рецидивов инфекции мочевыводящих путей

Автор: Москвина З.В., Болдырева М.Н., Россоловская К.А., Спивак Л.Г.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Инфекционно-воспалительные заболевания

Статья в выпуске: 1 т.17, 2024 года.

Бесплатный доступ

Введение. Профилактика инфекций мочевыводящих путей (ИМП) является актуальной проблемой в связи с их большой распространенностью. Регулярное использование антибиотиков, особенно в случаях рецидивирующей инфекции мочевых путей (РИМП), способствует формированию устойчивых штаммов микроорганизмов и развитию перекрестной антибиотикорезистентности. Именно поэтому возрастает актуальность поиска альтернативных неантибактериальных средств для лечения и профилактики воспалительных заболеваний мочевыводящих путей.

D-манноза, проантоцианидины, инфекции мочевыводящих путей, уропатогенная кишечная палочка, факторы вирулентности, адгезин fimh, профилактика, неантибактериальные средства

Короткий адрес: https://sciup.org/142241804

IDR: 142241804   |   DOI: 10.29188/2222-8543-2024-17-1-128-136

Список литературы Роль D-маннозы и проантоцианидинов клюквы в профилактике рецидивов инфекции мочевыводящих путей

  • Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011. Open Forum Infect Dis 2017;4(1):1-7. https://doi.org/10.1093/ofid/ofw281.
  • Гаджиева З.К., Казилов Ю.Б. Особенности подхода к профилактик рецидивирующей инфекции нижних мочевыводящих путей. Урология 2016;(3S3):65–76. [Gadzhieva Z.K., Kazilov Yu.B. The features in preventing recurrent lower urinary tract infection. Urologiya = Urologiia 2016;(3S3):65–76. (In Russian)].
  • Плеханов А.Н., Дамбаев А.Б. Инфекция мочевых путей: эпидемиология, этиология, патогенез, факторы риска, диагностика. Бюллетень восточно-сибирского научного центра Сибирского отделения Российской Академии Медицинских Наук 2016;107(1):70–4. [Plekhanov A.N., Dambaev A.B. Urinary tract infection: epidemiology, etiology, pathogenesis, risk factors, diagnosis. Byulleten' Vostochno-Sibirskogo Nauchnogo Tsentra Sibirskogo Otdeleniya Rossiyskoy Akademii Meditsinskikh Nauk = Bulletin Of The East Siberian Research Center Of The Siberian Branch Of The Russian Academy Of Medical Sciences 2016;107(1):70–4. (In Russian)].
  • Набока Ю.Л., Алькина А.К., Коган М.И., Гудима И.А., Ибишев Х.С., Джалагония К.Т., Черницкая М.Л. Мониторинг микробиоты и антибиотикорезистентности уропатогенов в одном урологическом стационаре. Вестник урологии 2020;8(3):47–57. [Naboka Yu.L., Alkina A.K., Kogan M.I., Gudima I.A., Ibishev Kh.S., Jalagonia K.T., Chernitskaya M.L. Monitoring of microbiota and antibiotic resistance of uropathogens in one urological hospital. Vestnik urologii = Herald of Urology 2020;8(3):47–57. (In Russian)].
  • Raeispour M, Ranjbar R. Antibiotic resistance, virulence factors and genotyping of Uropathogenic Escherichia coli strains. Antimicrob Resist Infect Control 2018;7:118. https://doi.org/10.1186/s13756-018-0411-4.
  • Sherchan JB, Dongol A, Humagain S, Joshi A, Rana Magar S, Bhandari S. Antibiotic Susceptibility Pattern of Bacteria Causing Urinary Tract Infection. J Nepal Health Res Counc 2022;20(1):218–24. https://doi.org/10.33314/jnhrc.v20i01.4142.
  • Baines G, Banjoko A, Brair A, Gray J, Desai N, Cardozo L, et al. Antibiotic resistance in urinary tract infections: A re-visit after five years and experience over two sites. Post Reprod Health 2020;26(2):91–100. https://doi.org/10.1177/2053369120910039.
  • Палагин И.С., Сухорукова А.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С. и др. Состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевыводящих путей в России, Беларуси и Казахстане: результаты многоцентрового международного исследования «Дармис-2018». Урология 2020;(1):19–31. [Palagin I.S., Sukhorukova A.V., Dekhnich A.V., Eidelshtein M.V., Perepanova |T.S., Kozlov R.S., et al. Current state of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia, Belarus and Kazakhstan: results of the international multicenter study «DARMIS-2018». Urologiya = Urologiia 2020;(1):19–31. (In Russian)]. https://dx.doi.org/10.18565/urology.2020.1.19-31.
  • Langford BJ, Brown KA, Diong C, Marchand-Austin A, Adomako K, Saedi A, et al. The Benefits and Harms of Antibiotic Prophylaxis for Urinary Tract Infection in Older Adults. Clinical Infectious Diseases 2021;73(3):782–91. https://doi.org/10.1093/cid/ciab116.
  • World Healht Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. [Electronic resource]. URL: https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12.
  • Domenici L, Monti M, Bracchi C, Giorgini M, Colagiovanni V, Muzii L, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci 2016;20(13):2920–5.
  • Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies. Front Microbiol 2017;15(8):1566. https://doi.org/10.3389/fmicb.2017.01566.
  • Bouckaert J, Berglund J, Schembri M, de Genst E, Cools L, Wuhrer M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 2004;55(2):441–55. https://doi.org/10.1111/j.13652958.2004.04415.x.
  • Торшин И.Ю., Аполихина И.А., Громов А.Н., Громова О.А.Torshin IYu, Apolikhina IA, Gromov AN, Gromova OA. О свойствах D-маннозы: противовоспалительные и противоопухолевые эффекты. Экспериментальная и клиническая урология 2020;12(2):164–170. [Torshin I.Yu., Apolikhina I.A., Gromov A.N., Gromova O.A. Torshin IYu, Apolikhina IA, Gromov AN, Gromova OA. About the properties of D-mannose: anti-inflammatory and antitumor effects. Eksperimental'naya i klinicheskaya urologiya = Experimental and Clinical Urology 2020;12(2):164–70. https://doi.org/10.29188/2222-8543-2020-12-2-164-170. (In Russian)].
  • Medus ML, Gomez GE, Zacchi LF, Couto PM, Labriola CA, Labanda MS, et al. N-glycosylation Triggers a Dual Selection Pressure in Eukaryotic Secretory Proteins. Sci Rep 2017;7(1):8788. https://doi.org/10.1038/s41598-017-09173-6.
  • Zhang D, Chia C, Jiao X, Jin W, Kasagi S, Wu R, et al. D-mannose induces regulatory T cells and suppresses immunopathology. Nat Med 2017;23(9):1036–45. https://doi.org/10.1038/нм.4375.
  • Alton G, Kjaergaard S, Etchison JR, Skovby F, Freeze HH. Oral ingestion of mannose elevates blood mannose levels: a first step toward a potential therapy for carbohydrate-deficient glycoprotein syndrome type I. Biochem Mol Med 1997;60(2):127–33. https://doi.org/10.1006/bmme.1997.2574.
  • Ganda OP, Soeldner JS, Gleason RE, Cleator IG, Reynolds C. Metabolic effects of glucose, mannose, galactose, and fructose in man. J Clin Endocrinol Metab 1979;49(4):616–22. https://doi.org/10.1210/jcem-49-4-616.
  • Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: A randomized clinical trial. World J Urol 2014;32(1):79–84. https://doi.org/10.1007/s00345-013-1091-6.
  • Porru D, Parmigiani A, Tinelli C, Barletta D, Choussos D, Di Franco C, et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J Clinic Urol 2014;7(3):208–13. https://doi.org/10.1016/S1569-9056(13)61373-1.
  • Palleschi G, Carbone A, Zanello PP, Mele R, Leto A, Fuschi A, et al. Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation. Archivio Italiano di Urologia e Andrologia 2017;89(1):45-50. https://doi.org/10.4081/aiua.2017.1.45.
  • Del Popolo G, Nelli F. Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment. Arch Ital Urol Androl 2018;90(2):101–3. https://doi.org/10.4081/aiua.2018.2.101.
  • Phé V, Pakzad M, Haslam C, Gonzales G, Curtis C, Porter B, et al. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol Urodyn 2017;36(7):1770–5. https://doi.org/10.1002/nau.23173.
  • Marchiori D, Zanello PP. Efficacy of N-acetylcysteine, D-mannose and Morinda citrifolia to Treat Recurrent Cystitis in Breast Cancer Survivals. In Vivo 2017;31(5):931–6. https://doi.org/10.21873/invivo.11149.
  • Genovese C, Davinelli S, Mangano K, Tempera G, Nicolosi D, Corsello S, и др. Effects of a new combination of plant extracts plus d-mannose for the management of uncomplicated recurrent urinary tract infections. Journal of Chemotherapy 2018;30(2):107–14. https://doi.org/10.1080/1120009X.2017.1393587.
  • Берников А.Н., Ходырева Л.А., Арефьева О.А. Российское проспективное исследование по изучению эффективности и безопасности Уронекст® в параллельных группах у женщин с обострением хронического рецидивирующего цистита. АБВ-пресс 2022:60. [Ernikov A.N., Khody-reva L.A., Arefieva O.A. Russian prospective study to study the effectiveness and safety of Uronext® in parallel groups in women with exacerbation of chronic recurrent cystitis. ABV-press 2022:60].
  • Тевлин К.П., Ханалиев Б.В., Тевлин Д.К. Свойства и безопасность комбинированной биологически активной добавки Уронекст в комплексном лечении острого (обострение хронического) цистита у женщин с бактериальным вагинозом. Consilium Medicum 2021;23(7):571–8. [Tevlin K.P., Khanaliev B.V., Tevlin D.K. Properties and safety of the combined dietary supplement Uronext in the complex treatment of acute (exacerbation of chronic) cystitis in women with bacterial vaginosis. Consilium Medicum 2021;23(7):571–8. (In Russian)]. https://doi.org/10.26442/20751753.2021.7.201061.
  • Шорманов И.С., Соловьев А.С., Чирков И.А., Щедров Д.Н., Красняк С.С., Шадеркин И.А. Возможности препаратов на основе D-маннозы и растительных компонентов в лечении и профилактике рецидивирующих инфекций нижних мочевых путей у женщин. Урологические ведомости 2022;12(1):13–20. [Shormanov I.S., Solovyov A.S., Chirkov I.A., Shchedrov D.N., Krasnyak S.S., Shaderkin I.A. Opportunities of drugs based on D-mannose and herbal components in the treatment and prevention of recurrent lower urinary tract infections in women. Urologicheskiye vedomosti = Urology reports 2022;12(1):13–20. (In Russian)]. https://doi.org/https://doi.org/10.17816/uroved84084.
  • Неймарк А.И., Неймарк Б.А., Ноздрачев Н.А., Ковалева Ю.С, Раздорская М.В., Мельник М.А. Возможности профилактики посткоитального цистита. Урология 2022;(3):33-40. [Neimark A.I., Neimark B.A., Nozdrachev N.A., Kovaleva Yu.S., Razdorskaya M.V., Melnik M.A. Possibilities for the prevention of postcoital cystitis. Urologiya = Urologiia 2022;(3):33-40. (In Russian)]. https://dx.doi.org/10.18565/urology.2022.3.33-41.
  • Слесаревская М.Н., Кузьмин И.В., Краева Л.А., Смирнова Е.В. Эффективность комбинированной биологически активной добавки Уронекст у женщин с рецидивирующими циститами: клинико-микробиологическое исследование. Экспериментальная и клиническая урология 2022;15(2):140-8. [Slesarevskaya M.N., Kuzmin I.V., Kraeva L.A., Smirnova E.V. The effectiveness of the combined dietary supplement Uronext in women with recurrent cystitis: a clinical microbiological study. Eksperimental'naya i klinicheskaya urologiya = Experimental and Clinical Urology 2022;15(2):140-8. (In Russian)]. https://doi.org/10.29188/2222-8543-2022-15-2-140-148.
  • Аль-Шукри А.С., Максимова А.В., Дуб Н.И., Костюков С.В., Манченко А.А., Майоров И.Д., и соавт. Профилактика развития катетер-ассоциированных инфекций мочевыделительной системы у пациентов в раннем послеоперационном периоде. Урология 2023;(2):10-6. [Al-Shukri A.S., Maksimova A.V., Dub N.I., Kostyukov S.V., Manchenko A.A., Mayorov I.D., et al. Prevention of the development of catheter-associated urinary system infections in patients in the early postoperative period. Urologiya = Urologiia 2023;(2):10-6. (In Russian)]. https: //dx.doi.org/10.18565/urology.2023.2.00-00.
  • Spaulding CN, Klein RD, Ruer S, Kau AL, Schreiber HL, Cusumano ZT, et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature 2017;546(7659):528–32. https://doi.org/10.1038/nature22972.
  • Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 2004;55(2):441–55. https://doi.org/10.1111/j.13652958.2004.04415.x.
  • Scribano D, Sarshar M, Prezioso C, Lucarelli M, Angeloni A, Zagaglia C, et al. d-Mannose Treatment neither Affects Uropathogenic Escherichia coli Properties nor Induces Stable FimH Modifications. Molecules 2020;25(2)316. https://doi.org/10.3390/molecules25020316.
  • Blumberg JB, Camesano TA, Cassidy A, Kris-Etherton P, Howell A, Manach C, et al. Cranberries and Their Bioactive Constituents in Human Health. Advances in Nutrition 2013;4(6):618–32. https://doi.org/10.3945/an.113.004473.
  • Gupta K, Chou MY, Howell A, Wobbe C, Grady R, Stapleton AE. Cranberry Products Inhibit Adherence of P-Fimbriated Escherichia Coli to Primary Cultured Bladder and Vaginal Epithelial Cells. Journal of Urology 2007;177(6):2357–60. https://doi.org/10.1016/j.juro.2007.01.114.
  • Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry 2005;66(18):2281–91. https://doi.org/10.1016/j.phytochem.2005.05.022.
  • Howell AB, Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized doubleblind study. BMC Infect Dis 2010;10(1):94. https://doi.org/10.1186/1471-2334-10-94.
  • Lavigne JP, Bourg G, Combescure C, Botto H, Sotto A. In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules. Clinical Microbiology and Infection 2008;14(4):350–5. https://doi.org/10.1111/j.1469-0691.2007.01917.x.
  • Babar A, Moore L, Leblanc V, Dudonné S, Desjardins Y, Lemieux S, et al. High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial. BMC Urol 2021;21(1):44. https://doi.org/10.1186/s12894-021-00811-w.
  • Fu Z, Liska D, Talan D, Chung M. Cranberry Reduces the Risk of Urinary Tract Infection Recurrence in Otherwise Healthy Women: A Systematic Review and Meta-Analysis. J Nutr 2017;147(12):2282–8. https://doi.org/10.3945/jn.117.254961.
  • Xia J yue, Yang C, Xu D feng, Xia H, Yang L gang, Sun G ju. Consumption of cranberry as adjuvant therapy for urinary tract infections in susceptible populations: A systematic review and meta-analysis with trial sequential analysis. PLoS One 2021;16(9):e0256992. https://doi.org/10.1371/journal.pone.0256992.
  • Williams G, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2023;4(4):CD001321. https://doi.org/10.1002/14651858.CD001321.pub6.
  • Сычев Д.А. Применение препаратов клюквы в урологической практике: взгляд клинического фармаколога. Эффективная фармакотерапия. Урология и Нефрология 2011;(2):44–8. [Sychev D.A. The use of cranberry preparations in urological practice: the view of a clinical pharmacologist. Effektivnaya farmakoterapiya. Urologiya i Nefrologiya = Effective pharmacotherapy. Urology and Nephrology 2011;(2):44–8. (In Russian)].
  • Ulrey RK, Barksdale SM, Zhou W, van Hoek ML. Cranberry proanthocyanidins have anti-biofilm properties against Pseudomonas aeruginosa. BMC Complement Altern Med 2014;14(1):499. https://doi.org/10.1186/1472-6882-14-499.
  • Maisuria VB, Okshevsky M, Déziel E, Tufenkji N. Proanthocyanidin Interferes with Intrinsic Antibiotic Resistance Mechanisms of Gram‐Negative Bacteria. Advanced Science 2019;6(15):1802333. https://doi.org/10.1002/advs.201802333.
  • Rădulescu D, David C, Turcu FL, Spătaru DM, Popescu P, Văcăroiu IA. Combination of cranberry extract and D-mannose - possible enhancer of uropathogen sensitivity to antibiotics in acute therapy of urinary tract infections: Results of a pilot study. Exp Ther Med 2020;20(4):3399–406. https://doi.org/10.3892/etm.2020.8970.
  • Scharf B, Sendker J, Dobrindt U, Hensel A. Influence of Cranberry Extract on Tamm-Horsfall Protein in Human Urine and its Antiadhesive Activity Against Uropathogenic Escherichia coli. Planta Med 2019;85(2):126–38. https://doi.org/10.1055/a-0755-7801.
  • DE Leo V, Cappelli V, Massaro MG, Tosti C, Morgante G. Evaluation of the effects of a natural dietary supplement with cranberry, Noxamicina® and D-mannose in recurrent urinary infections in perimenopausal women. Minerva Ginecol 2017;69(4):336–41. https://doi.org/10.23736/ S0026-4784.17.04074-6.
  • Vicariotto F. Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: a pilot study. J Clin Gastroenterol 2014;48(Suppl 1):S96-101. https://doi.org/10.1097/MCG.0000000000000224.
  • Salinas-Casado J, Méndez-Rubio S, Esteban-Fuertes M, Gómez-Rodríguez A, Vírseda-Chamorro M, Luján-Galán M, et al. Large study (283 women) on the effectiveness of Manosar®: 2 g of d-mannose + 140 mg of proanthocyanidins (PAC), of prolonged release. Arch Esp Urol 2020;73(6):491–8.
  • Garofalo L, Nakama C, Hanes D, Zwickey H. Whole-Person, Urobiome-Centric Therapy for Uncomplicated Urinary Tract Infection. Antibiotics 2022;11(2):218. https://doi.org/10.3390/ antibiotics11020218.
  • Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided Midstream Urine Culture and Acute Cystitis in Premenopausal Women. New England Journal of Medicine 2013;369(20):1883–91. https://doi.org/10.1056/NEJMoa1302186.
  • Eckford SD, Keane DP, Lamond E, Jackson SR, Abrams P. Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre-menopausal women. Br J Urol 1995;76(1):90–3. https://doi.org/10.1111/j.1464-410x.1995.tb07839.x.
  • Castelló T, Girona L, Gómez MR, Mena Mur A, Garcia L. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. Spinal Cord 1996;34(10):592–3. https://doi.org/10.1038/sc.1996.105.
  • Ochoa-Brust GJ, Fernández AR, Villanueva-Ruiz GJ, Velasco R, Trujillo-Hernández B, Vásquez C. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand 2007;86(7):783–7. https://doi.org/10.1080/00016340701273189.
  • Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H, Naber KG. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int 2018;101(3):327–36. https://doi.org/10.1159/000493368.
  • Beerepoot MAJ, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic Prophylaxis for Recurrent Urinary Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Urol 2013;190(6):1981–9. https://doi.org/10.1016/j.juro.2013.04.142.
  • Taha Neto KA, Nogueira Castilho L, Reis LO. Oral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systematic review with meta-analysis. Actas Urol Esp 2016;40(4):203–8. https://doi.org/10.1016/j.acuro.2015.04.008.
  • Costantini E, Lazzeri M, Pistolesi D, Del Zingaro M, Frumenzio E, Boni A, et al. Morphological Changes of Bladder Mucosa in Patients Who Underwent Instillation with Combined Sodium Hyaluronic Acid-Chondroitin Sulphate (Ialuril®). Urol Int 2013;91(1):81–8. https://doi.org/10.1159/000345047.
  • Madersbacher H, van Ophoven A, van Kerrebroeck PEVA. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans-A review. Neurourol Urodyn 2013;32(1):9–18. https://doi.org/10.1002/nau.22256.
  • Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol 2011;3(5):223–32. https://doi.org/10.1177/1756287211418723.
  • Perrotta C, Albert X, Aznar M. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database of Systematic Reviews 2008;16(2):CD005131. https://doi.org/10.1002/14651858.CD005131.pub2.
  • Mohanty S, Kamolvit W, Hertting O, Brauner A. Vitamin D strengthens the bladder epithelial barrier by inducing tight junction proteins during E. coli urinary tract infection. Cell Tissue Res 2020;380(3):669-73. https://doi.org/10.1007/s00441-019-03162-z.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp